 |
|
|
| |
All Oral Fixed-Dose Combination Ledipasvir/Sofosbuvir With Or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: the Phase 3 ION-1 Study
|
| |
| |
Reported by Jules Levin
EASL 2014 April 9-13 London, UK
Alessandra Mangia,1 Patrick Marcellin,2 Paul Kwo,3
Graham R. Foster,4 Maria Buti,5 Norbert Bräu,6 Andrew Muir,7
Jenny C. Yang,8 Hongmei Mo,8 Xiao Ding,8 Phil S. Pang,8
William T. Symonds,8 John G. McHutchison,8 Stefan Zeuzem,9 Nezam Afdhal10
1Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy; 2Centre Hospitalier Universitaire Beaujon, Clichy-sous-Bois, France; 3Indiana University School of Medicine, Indianapolis, IN, USA; 4Queen Mary's University of London, Barts Health, UK; 5Hospital Universitario Valle de Hebrón, Barcelona, Cataluña, Spain; 6Mount Sinai School of Medicine, New York, NY, USA; 7Duke University Medical Center, Durham, NC, USA; 8Gilead Sciences, Inc., Foster City, CA; 9Johann Wolfgang Goethe University, Frankfurt, Germany; 10Beth Israel Deaconess Medical Center, Boston, MA, USA
|
| |
|
|
|
|
|
